Participants
We included symptomatic and asymptomatic children in both inpatient and
ambulatory settings seeking care at CHCO who were immunocompromised and
had at least 1 positive SARS-CoV-2 PCR conducted at the CHCO Clinical
Microbiology Laboratory. Children were defined as immunocompromised if
they were a patient of the CCBD receiving active treatment for cancer
(solid and liquid tumor), post bone marrow/stem cell transplant or
chimeric antigen receptor- (CAR) T cell therapy with active documented
immunodeficiency, had a primary or secondary immunodeficiency (e.g. HIV)
or received immunosuppressive medications. We excluded children with
normal immune function and those not currently on treatment for their
cancer diagnosis, fully immune reconstituted post-bone marrow
transplant, and those with a positive SARS-CoV-2 test at outside
facilities only. Our institution requires ICC to have two consecutive
negative SARS-CoV-2 PCR tests collected at least 24 hours apart and 21
days from the patient’s initial positive test in order to be removed
from isolation.